Amy is a managing partner at Polaris Partners who focuses on investing in healthcare companies and early stage biotech start-ups.
She serves as chair of the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY) and is a member of the Board of Directors of Elevance Health (NYSE: ELV). She also represents Polaris as a director of Kallyope, QurAlis, and Larkspur. Amy serves on the Boards of Action Against Hunger, Mount Sinai Hospital (where she co-chairs the Innovations Committee), and the California Institute of Technology. She is a member of Singapore’s Human Health and Potential International Advisory Council, and serves on Singapore’s Research, Innovation and Enterprise Council (REIC) in addition to several boards in Singapore.
Amy joined Polaris in 2014, and in 2017 she co-founded the Polaris Innovation Fund, which she continues to manage today, in addition to her role as a managing partner of the Polaris main funds.
Before Polaris, Amy worked at Pfizer, where she held several roles, beginning with general counsel and moving to the business side as president of both Pfizer Nutrition and Pfizer Consumer Healthcare. She practiced law as a partner at DLA Piper and began her career in litigation with Cleary Gottlieb Steen & Hamilton in 1991.
Amy has received numerous awards, including Forbes’ 50 Over 50 list in 2025, Fortune Magazine’s 50 Most Powerful Women in Business, the Margaret Brent Women Lawyers of Achievement Award, Scientific American’s Worldview 100 List, and Fierce Biotech’s Top 15 Women in Biotech.
In July 2014, Amy joined Harvard Business School’s Faculty as a Senior Lecturer, where she is currently teaching.
Amy is a Phi Beta Kappa graduate of Wesleyan University and Yale Law School.